JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
about
Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factorsRuxolitinib for myelofibrosis--an update of its clinical effects.Loss of wild-type Jak2 allele enhances myeloid cell expansion and accelerates myelofibrosis in Jak2V617F knock-in miceMyelofibrotic transformations of polycythemia vera and essential thrombocythemia are morphologically, biologically, and prognostically indistinguishable from primary myelofibrosis.Decrease in JAK2 V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera.The effect of long-term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis.Correlations between Janus kinase 2 V617F allele burdens and clinicohematologic parameters in myeloproliferative neoplasms.JAK2 Allele Burden in the Myeloproliferative Neoplasms: Effects on Phenotype, Prognosis and Change with Treatment.Comprehensive review of JAK inhibitors in myeloproliferative neoplasms.JAK2V617F Allele Burden Measurement in Peripheral Blood of Iranian Patients with Myeloproliferative Neoplasms and Effect of Hydroxyurea on JAK2V617F Allele Burden.Overview of Transgenic Mouse Models of Myeloproliferative Neoplasms (MPNs).Laboratory Investigation of Myeloproliferative Neoplasms (MPNs): Recommendations of the Canadian Mpn Group.Correlation between JAK2 allele burden and pulmonary arterial hypertension and hematological parameters in Philadelphia negative JAK2 positive myeloproliferative neoplasms. An Egyptian experience.Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 359 patients of the AGIMM group.Expression analysis of microRNA-125 in patients with polycythemia vera and essential thrombocythemia and correlation with JAK2 allele burden and laboratory findings.Assessment of the interlaboratory variability and robustness of JAK2V617F mutation assays: A study involving a consortium of 19 Italian laboratories.Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon α-treated polycythemia vera patientsAge-related differences in disease characteristics and clinical outcomes in polycythemia vera.JAK2V617F mutation status and allele burden in classical Ph-negative myeloproliferative neoplasms in Japan.Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis.Leukocytosis in polycythemia vera and splenomegaly in essential thrombocythemia are independent risk factors for hemorrhage.Patient characteristics and outcomes in adolescents and young adults with classical Philadelphia chromosome-negative myeloproliferative neoplasms.Consequences of the JAK2V617F allele burden for the prediction of transformation into myelofibrosis from polycythemia vera and essential thrombocythemia.
P2860
Q26777265-DBE0B498-BDB6-45ED-9B03-E3E605FA25DAQ33411502-54929495-E8FD-499E-A2CA-8E1948187E9CQ33983970-05B34C69-964F-4195-8986-61788D8DE03CQ35386991-18493325-A0C2-427D-9649-62624B841313Q35944657-3D170B50-1CC1-4BD7-B788-852819D18697Q36091279-D3A53FC7-4E8A-45D4-82A9-289E686A8CD6Q36365017-8E593FC6-DD00-4C66-96AC-466FE0F01ADBQ36612537-8BAAECBD-878C-4E6B-A4ED-32BBB8A26B90Q36776428-9D44F9FB-30CF-4020-85EF-0E44264A21F9Q36954379-2D10F802-A3A9-4428-97E8-49F6F4644C11Q38699339-A00E6137-B8EB-4D12-B1AA-CCE8031D2E4BQ38816384-13217840-2014-49BB-8873-702564EE4AFCQ38911553-13A7BA4A-70AF-4534-A870-7E88B0300753Q39869997-BAC4249A-DE6E-4245-B159-5B8F9977FA34Q40901657-7D91E9F6-A1EF-4B68-946E-E6EE3E72624BQ42062133-DA238524-256C-4664-9ACA-2837EF4C6018Q42361982-952D359D-FA49-4877-BCF4-DFDF3A609BAAQ45382720-78E4CE8E-FD40-485C-BA34-A0F48BD9AC95Q45797468-2B5976E5-84DA-4C5C-98D3-2721C9A5EC94Q46636672-445E1CA6-85EE-41BE-912F-B42A72CE3CA6Q48548146-C08E678F-44F7-4493-84DB-08F6C4C08896Q49978793-3C127AF6-02FA-4545-B2AD-5164903239B0Q51270030-E288EA8F-359C-4FF5-8049-4C818DD76444
P2860
JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@ast
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@en
type
label
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@ast
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@en
prefLabel
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@ast
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@en
P2093
P2860
P1433
P1476
JAK2(V617F) allele burden in p ...... stantially affected by therapy
@en
P2093
Amy V Jones
Fernando Adriano
Katherine Vandris
Paul J Christos
Richard T Silver
P2860
P304
P356
10.1016/J.LEUKRES.2010.06.017
P577
2010-07-22T00:00:00Z